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Introduction {#sec1}
============

The complement system, a critical part of the immune system, helps defend against invading pathogens, promote inflammation, and clear damaged cells and debris ([@bib17], [@bib19]). In the central nervous system (CNS), complement components have been found to play important roles in neuron survival and synaptic pruning under both normal and disease conditions ([@bib22], [@bib30], [@bib47], [@bib54]). However, the regulatory mechanisms for complement expression and function in the CNS are still largely unknown.

The *SUSD4* (Sushi domain-containing protein 4) gene resides on chromosome 1q41 and encodes a 49-kD transmembrane protein containing four extracellular Sushi domain motifs ([@bib60]). The Sushi domain, also known as the complement control protein domain, is commonly involved in protein-protein interactions. Many complement regulators are constructed with complement control protein domains ([@bib16], [@bib26]). SUSD4 functions as a complement system regulator, as it has been shown to bind to the C1 complex and complement component C1q and block the activation of the complement cascade by interrupting the formation of C3 convertase ([@bib20]). However, SUSD4 has also been reported to inhibit the alternative pathway warranting further studies to clarify the SUSD4 mechanisms of action on the complement system.

In humans, the CNS is a major site of SUSD4 expression ([@bib20]). Deletion of the *SUSD4* gene, together with several other genes, frequently occurs in patients with 1q41q42 microdeletion syndrome ([@bib49]), who generally exhibit seizures, significant developmental delay, and intellectual disability, as well as multiple congenital abnormalities, along a variable phenotypic spectrum. It is not known if *SUSD4*, when included in the deletion interval, contributes to the patients\' clinical presentation. Because the physiologic role of SUSD4 in the mammalian nervous system was not yet established, we used *Susd4* knockout (KO) mice to identify the neurologic functions of *Susd4*. We found that *Susd4* deletion affects both behavioral phenotypes and neuronal morphology in these mice, demonstrating an important CNS role for SUSD4, and that its deletion may contribute to the phenotypic spectrum of patients with 1q41q42 microdeletion syndrome.

Results {#sec2}
=======

*Susd4* KO Mice Exhibit Behavioral Abnormalities {#sec2.1}
------------------------------------------------

We first determined the relative tissue expression of *Susd4* mRNA in wild-type (WT) mice using qPCR (targeting exon 1--2 and exon 5--6 junctions) ([Figure 1](#fig1){ref-type="fig"}A). *Susd4* mRNA expression was highest in the WT brain and was detectable at lower levels in lung, liver, kidney, and testis, as well as during development from embryonic day 11--17.Figure 1*Susd4* KO Mice Exhibit Behavioral Abnormalities(A) Relative mRNA expression of Susd4 determined by qPCR in a panel of 12 different tissues from WT mice, as well as *Susd4* KO mouse brain tissue (far right). qPCR assays for Susd4 were performed using probes spanning exons 1 and 2 (Susd4~exon1-2~) and exons 5 and 6 (Susd4~exon5-6~) (n = 3). mRNA expression was normalized to Gapdh mRNA expression. E, embryonic day; N.D., not detectable.(B) Horizontal balance-beam test. Time for mice to cross 80-cm-long beams of different widths was recorded. Width of the beams: beam 1 is 24 mm; beam 2 is 12 mm; beam 3 is 9.5 mm. *Susd4* KO, n = 17; WT, n = 11.(C) Accelerating-rotarod test. Latency time for mice to fall from the rotarod was recorded. *Susd4* KO, n = 17; WT, n = 15.(D--F) Elevated zero-maze test. (D) Time mice spent in closed and open arms of the maze was recorded for 5 min. (E) Number of open-arm entries by mice was recorded for 5 min. (F) Total distance mice traveled in the open arms was recorded for 5 min *Susd4* KO, n = 17; WT, n = 15.(G--I) Open-field test. (G) Representative tracing of the path traveled by a WT and a *Susd4* KO mouse over 30 min in the test. The blue dot represents the starting point and the red dot represents the endpoint of the path. (H) Total distance mice traveled was recorded for 30 min. (I) Time mice spent in the center of the field was recorded for 30 min *Susd4* KO, n = 17; WT, n = 15.(J) Cylinder test. Number of rears by mice was recorded for 90 s *Susd4* KO, n = 17; WT, n = 15.(K and L) Hole-board test. (K) Total distance mice traveled was recorded for 5 min. (L) Number of head pokes by mice into holes was recorded for 5 min *Susd4* KO, n = 17; WT, n = 15.Data represent the mean ± SEM. ∗: p \< 0.05; ∗∗: p \< 0.005; ∗∗∗: p \< 0.0005; ∗∗∗∗: p \< 0.0001. For a complete behavioral phenotyping battery, see also [Table S1](#mmc1){ref-type="supplementary-material"} and [Figure S1](#mmc1){ref-type="supplementary-material"}.

To identify the physiologic functions of the S*usd4* gene, we utilized a *Susd4* KO mouse model ([@bib58]). Expression of *Susd4* mRNA was not detectable in *Susd4* KO mouse brain, confirming the presence of a null *Susd4* allele ([Figure 1](#fig1){ref-type="fig"}A, far right). *Susd4* KO mice were viable, fertile, and grew normally ([@bib58]) (see also [Table S1](#mmc1){ref-type="supplementary-material"}). We subsequently performed behavioral phenotyping to determine if the *Susd4* deletion would affect nervous-system functions. Compared with WT mice, *Susd4* KO mice exhibited defects in motor and coordination function, as revealed by horizontal balance-beam and accelerating-rotarod tests. In the balance-beam test, as the width of the balance beam decreased, which increased the demand for fine locomotor control, the mean time that the *Susd4* KO mice spent to cross the beam was significantly longer than that of WT mice ([Figure 1](#fig1){ref-type="fig"}B). In the accelerating-rotarod test, the mean latency time that *Susd4* KO mice stayed on the rotarod as it accelerated was significantly shorter, indicating poorer motor coordination, than that of WT mice ([Figure 1](#fig1){ref-type="fig"}C). Gross sensorimotor and locomotor functions were not affected as assessed by Shirpa screening and DigiGait tests ([Table S1](#mmc1){ref-type="supplementary-material"}, [Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B).

Further behavioral testing indicated that S*usd4* KO mice exhibited anxiety-like behavioral phenotypes ([@bib10], [@bib21]). In the elevated zero-maze test *Susd4* KO mice spent significantly more mean time in the closed arms (and significantly less mean time in the open arms) ([Figure 1](#fig1){ref-type="fig"}D), and the mean frequency of open-arm entries ([Figure 1](#fig1){ref-type="fig"}E) and the mean distance traveled in the open arms were significantly less than those observed in WT mice ([Figure 1](#fig1){ref-type="fig"}F). In the open-field test, both the mean total distance traveled ([Figures 1](#fig1){ref-type="fig"}G and 1H) and the mean time spent in the center of the field were significantly less for *Susd4* KO mice than for WT mice ([Figures 1](#fig1){ref-type="fig"}G and 1I). In addition, the *Susd4* KO mice undertook significantly reduced exploratory activity in the cylinder test (mean number of rears; [Figure 1](#fig1){ref-type="fig"}J) and the hole-board test (mean total distance traveled; [Figure 1](#fig1){ref-type="fig"}K) and mean number of head-poking into holes ([Figure 1](#fig1){ref-type="fig"}L) compared with WT mice. Learning and memory functions were generally not impaired in the *Susd4* KO mice as revealed by Morris water maze testing ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

*Susd4* KO Mice Exhibit Abnormal Neuronal Morphology and Hypertrophic Microglia {#sec2.2}
-------------------------------------------------------------------------------

Bielschowsky silver staining is a histochemical method to visualize nerve fibers and has been used in studies of Alzheimer\'s disease and other neurodegenerative disorders to identify axonal or neurofibrillary pathology ([@bib52], [@bib57], [@bib63]). Using this stain, we found an abnormal morphology of basket cells, termed "hairy" ([@bib13]), indicating a dense and tangled axonal plexus surrounding Purkinje cell soma, in the cerebellum of *Susd4* KO mice that was not found in the cerebellum of WT mice ([Figure 2](#fig2){ref-type="fig"}A). Changes in neurofilament heavy chain phosphorylation status is an indicator for axonal degeneration in neurological diseases and can be detected with the SMI-31 antibody ([@bib11], [@bib43], [@bib55], [@bib62]). Immunostaining with SMI-31 revealed that the hairy basket cell dendrites enclosing the cell bodies of calbindin-positive Purkinje neurons in the *Susd4* KO mice prominently expressed phosphorylated neurofilament heavy chain ([Figures 2](#fig2){ref-type="fig"}B and 2C). Abnormal hairy basket cells are believed to be associated with Purkinje cell degeneration ([@bib13]), although no significant difference in the numbers of cerebellar Purkinje cells in *Susd4* KO and WT mice was found ([Figure S2](#mmc1){ref-type="supplementary-material"}). The abnormal basket cell morphology may be related to the motor function defects observed in *Susd4* KO mice.Figure 2*Susd4* KO Mice Exhibit Abnormal Neuronal Morphology and Hypertrophic Microglia(A) Bielschowsky silver staining of cerebellum. Top panels, representative sagittal view of the whole cerebellum for a WT and a *Susd4* KO mouse. Arrows indicate the dense-appearing basket cell layer in the *Susd4* KO mouse cerebellum relative to the WT tissue. Scale bar, 200 μm. Lower panels, representative higher magnification view shows Purkinje cell layer and basket cells (arrows). Note "hairy" appearance of basket cells in the *Susd4* KO specimen. Scale bar, 20 μm(B) Representative immunostaining with SMI-31antibody, labeling phosphorylated neurofilament heavy chain (green), and calbindin antibody, labeling Purkinje cells (red), in cerebellum sections from *Susd4* KO and WT mice; scale bar, 20 μm.(C) Representative higher-magnification view showing "hairy" basket cell dendrites (SMI-31 immunostaining in green) surrounding Purkinje cell soma (calbindin immunostaining in red); scale bar, 10 μm.(D) Golgi-Cox staining of brains. Representative images of dendritic spines for WT and *Susd4* KO mice.(E) Quantification of the number of spines per micrometer dendrite on secondary or tertiary branches from both apical and basal parts of the pyramidal cells in hippocampal CA regions of WT and *Susd4* KO Golgi-stained mouse brains. Data represent the mean ± SEM. n = 3 mice per group; ∗∗∗∗: p \< 0.0001.(F) Iba1immunostaining (red) for microglia. Top panels, representative view of hippocampal regions from WT and *Susd4* KO mice. Scale bar, 40 μm. Lower panels, representative higher magnification view shows ramified resting microglia (arrows in top panel) in WT in contrast with hypertrophic microglia (arrow heads in top panel) in *Susd4* KO. CA, cornu ammonis. Scale bar, 10 μm.(G) Quantification of Iba1+ cells per square millimeter in hippocampal regions from WT and *Susd4* KO mice. Data represent the mean ± SEM. n = 3 mice per group. ∗: p \< 0.05.(H) Quantification of Iba1 fluorescence intensity/microglia from the stained hippocampal sections. Data represent the mean ± SEM. WT values were set to 1.0. n = 3 mice per group. ∗∗∗∗: p \< 0.0001. Nuclei were visualized with DAPI staining (blue) for (B), (C), and (F).

The Golgi-Cox impregnation method is a classical technique used to reveal the morphology of whole individual neurons, including dendritic spines ([@bib31], [@bib46]). Dendritic spines are small protrusions that receive inputs from axons at the synapse, which are important for regulation of neuron activities and connections. Abnormalities in dendritic spines, such as changes in spine number or density, may lead to neuron degeneration and cognitive disorders ([@bib15], [@bib40], [@bib50]). Using the Golgi-Cox staining technique, we found a significant reduction in dendritic spine density on the pyramidal cells in hippocampal CA region in *Susd4* KO mice compared with WT mice ([Figures 2](#fig2){ref-type="fig"}D and 2E).

Microglia, resident immune cells in the brain, are involved in neuronal synaptic pruning mediated by complement factors ([@bib59]). Immunostaining of microglia with Iba1 antibodies revealed dense hypertrophic morphology of microglia in the *Susd4* KO hippocampal sections compared with the classic ramified morphology of resting microglia in the WT hippocampus ([Figure 2](#fig2){ref-type="fig"}F). The *Susd4* KO microglia were increased in number and stained more intensely with Iba1 antibody ([Figures 2](#fig2){ref-type="fig"}G and 2H). These results suggest activation of microglia in the *Susd4* KO hippocampi, a process that has been correlated with elevated synaptic pruning ([@bib22]).

*Susd4* Is Highly Expressed in Hippocampal Neurons and Cerebellar Purkinje Cells {#sec2.3}
--------------------------------------------------------------------------------

Although *Susd4* is highly expressed in brain, its normal cellular expression in hippocampus and cerebellum---areas of abnormal neuronal morphology in *Susd4* KO mice---was not known. We initially tested three different commercial SUSD4 antibodies on mouse brain tissue sections, and all showed the same immunoreactivity in tissues from *Susd4* KO mice compared with WT mice, indicating a lack of sufficient antibody specificity. Therefore, we used the RNAscope Multiplex Fluorescent Assay to probe the cellular expression of *Susd4* mRNA. This *in situ* RNA hybridization assay allows simultaneous detection of three different mRNA targets per sample, with each target probe binding to a specific mRNA, each of which is then labeled with different fluorescence detectors. Initially, we used probes for Susd4 mRNA, Gfap mRNA (specific for astrocytes), and Rbfox (also known as NeuN) mRNA (specific for most neuronal types). As a specificity control for the *Susd4* probe we also hybridized sections from the *Susd4* KO mice, which showed no *Susd4* mRNA ([Figure 3](#fig3){ref-type="fig"}A). The WT mouse brain hippocampal CA layer and dentate gyrus were highly positive for NeuN mRNA (red) and *Susd4* mRNA (green) ([Figure 3](#fig3){ref-type="fig"}B). Gfap mRNA (cyan) was diffusely distributed ([Figure 3](#fig3){ref-type="fig"}B). At a higher-resolution view, *Susd4* mRNA was co-localized in cells expressing NeuN mRNA ([Figure 3](#fig3){ref-type="fig"}C) but not in cells expressing Gfap mRNA ([Figure 3](#fig3){ref-type="fig"}D). In the cerebellum of WT mice, the granular layer, which is adjacent to the Purkinje cell layer, was highly positive for NeuN mRNA (red). Purkinje cells do not express NeuN ([@bib36]). In WT mice, both the granular layer and Purkinje cell layer regions were positive for *Susd4* mRNA (green), with the large Purkinje cells showing an intense reaction. Gfap mRNA (cyan) expression was not enriched in either of these layers ([Figures 3](#fig3){ref-type="fig"}E and 3F). These results indicate that *Susd4* mRNA has relatively high expression in both hippocampal neurons and cerebellar Purkinje cells, which are areas that exhibited abnormal neuronal morphology in *Susd4* KO mice.Figure 3*Susd4* mRNA is Expressed in Neuronal Cells in WT BrainThe RNAscope Multiplex Fluorescent Assay was performed with sagittal brain sections from WT and *Susd4* KO mice. Sets of probes were used to detect mRNA expression of *Susd4* (green), NeuN (red), and Gfap (cyan) *in situ*. Nuclei were visualized with DAPI staining (blue).(A) Representative images from cortex sections show the assay specifically detects *Susd4* mRNA in WT but not in *Susd4* KO, whereas NeuN mRNA is detected in both. Scale bar, 20 μm.(B) *Susd4* mRNA is highly expressed in the hippocampus. Scale bar, 100 μm. CA, cornu ammonis; DG, dentate gyrus.(C and D) Representative higher-magnification views show that *Susd4* mRNA colocalizes with NeuN (C) but not Gfap (D). Scale bar, 10 μm.(E) *Susd4*mRNA is highly expressed in Purkinje cells not the granular cells in cerebellum. Scale bar, 40 μm. PCL, Purkinje cell layer; GL, granular layer.(F) Representative higher-magnification view shows the high expression of *Susd4* mRNA in Purkinje neurons. Scale bar, 10 μm.

We next determined if *Susd4* mRNA is also expressed in the oligodendrocyte lineage using an Olig2 probe ([@bib67]). Our results indicated that a subset of Olig2-expressing cells also express *Susd4* mRNA in the cortex and corpus callosum ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Approximately 35% of the total Olig2+ cells in the cortex and 7.5% of the total Olig2+ in the corpus callosum were also positive for *Susd4* ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D), similar to the levels of oligodendrocyte progenitors in these regions ([@bib65]). Although Olig2+ cells were reduced in the *Susd4* KO cortex compared with WT, myelin basic protein (MBP) expression was found to be marginally increased in the *Susd4* KO cerebrum, suggesting the level of myelination was not adversely affected ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3E). Numbers of Olig2+ cells in the corpus callosum were similar in *Susd4* KO and WT mice ([Figure S3](#mmc1){ref-type="supplementary-material"}D).

Brain C1q Protein Expression Is Increased in *Susd4* KO Mice {#sec2.4}
------------------------------------------------------------

In the nervous system, C1q is known to play critical roles in neuron dendritic pruning and synaptogenesis ([@bib6], [@bib9], [@bib34], [@bib42]). To determine if SUSD4 expression affects C1q levels in the brain, we investigated C1q protein expression in *Susd4* KO mice by both immunostaining and western blotting. Immunostaining of hippocampal sections showed that C1q fluorescence intensity was increased 1.5-fold in the *Susd4* KO mice, when compared with WT mice ([Figures 4](#fig4){ref-type="fig"}A--4C). In the cerebellum, C1q protein was found to be relatively highly expressed in the Purkinje cells of the anterobasal lobes of the *Susd4* KO mice compared with WT ([Figure 4](#fig4){ref-type="fig"}D).Figure 4Brain C1q Protein Expression Is Increased in *Susd4* KO Mice(A and B) Representative immunostaining for C1q (green) in the hippocampus sections of *Susd4* KO (A) and WT (B) mice; scale bar, 100 μm.(C) Quantification of C1q fluorescence intensity from the stained hippocampus sections. Data represent the mean ± SEM. WT values were set to 1.0. n = 3 mice per group. ∗∗∗∗: p \< 0.0001.(D) Representative immunostaining for C1q (green) and calbindin (red) in the cerebellum sections of *Susd4* KO and WT mice. Scale bar, 40 μm. Nuclei were visualized with DAPI staining (blue) for (A), (B), and (D).(E) Western blot analysis of C1q polypeptide levels in cerebellum lysates obtained from three WT and three *Susd4* KO mice. β-Actin was simultaneously detected on the same blot as a loading control. L, molecular weight ladder.(F) Quantification of C1q polypeptide expression from western blots. Expression was normalized to β-actin expression. Data represent the mean ± SEM. WT values were set to 1.0. ∗: p \< 0.05.(G) Representative immunostaining for C1q (green) and VGAT (red) in the WT and *Susd4* KO hippocampal sections. Circles indicate the C1q and VGAT colocalized puncta in the sections. Arrow heads point to dendrite colocalized C1q and VGAT in the *Susd4* KO section. Scale bar, 5 μm.(H) Quantification using ImageJ of percentage VGAT colocalized with C1q. Data represent the mean ± SEM. n = 3 mice per group. ∗∗∗∗: p \< 0.0001.(I) Western blot analysis of VGAT in hippocampal lysates obtained from three WT and four *Susd4* KO mice. β-Actin was detected on the same blot as a loading control.(J) Quantification of VGAT protein levels from western blots. Expression was normalized to β-actin expression. WT values were set to 1.0. ∗∗: p \< 0.005.

Western blotting with a monoclonal antibody to C1q indicated a 1.7-fold increase of constituent C1q expression in the cerebellum from the *Susd4* KO mice when compared with the cerebellum from WT mice ([Figures 4](#fig4){ref-type="fig"}E and 4F). C1qa mRNA levels in hippocampus and cerebellum of the *Susd4* KO mice compared with that of WT mice were not significantly different ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), suggesting that the difference in protein levels was post-transcriptional. We investigated downstream of the complement pathway by determining complement C3 levels by western blotting of hippocampal extracts from the *Susd4* KO and WT mice. The level of C3 was not significantly different nor was there evidence of altered C3 proteolysis ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D).

We determined, through co-staining of C1q and synaptic markers on *Susd4* KO and WT hippocampal sections, if there was increased deposition of C1q on neuronal synapses, which might lead to increased synaptic pruning in the *Susd4* KO brain. Co-localization analysis of inhibitory synaptic marker vesicular GABA transporter (VGAT) ([@bib53]) and C1q revealed a 2.5-fold increase of double-positive synapses in the *Susd4* KO ([Figures 4](#fig4){ref-type="fig"}G and 4H). Western blotting demonstrated that VGAT levels were decreased by about 20% in the hippocampus from the *Susd4* KO mice when compared with the hippocampus from WT mice ([Figures 4](#fig4){ref-type="fig"}I and 4J).

Co-localization analysis of excitatory synaptic marker, vesicular glutamate transporter 1 (VGlut1) and C1q revealed a 1.6-fold increase of double-positive synapses in the *Susd4* KO hippocampal sections ([Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H) ([@bib53]). The total VGlut1 protein level measured by western blotting was not statistically significant between *Susd4* KO and the WT hippocampus ([Figures S4](#mmc1){ref-type="supplementary-material"}I and S4J). These results show that, in the absence of SUSD4, C1q levels are elevated in the brain with increased deposition at synapses, which may lead to synaptic loss through pruning.

Discussion {#sec3}
==========

SUSD4 has been identified as a novel complement regulator that binds to the complement component C1q ([@bib20], [@bib60]); however, its *in vivo* roles in the CNS are still largely unknown. Here, in the *Susd4* KO mouse model we found increased C1q levels in the brain, activation status of microglia, neuronal morphology in the hippocampus and cerebellum, and motor and anxiety-like behavioral phenotypes.

The abnormal behavioral changes indicative of increased anxiety and decreased motor function observed in the *Susd4* KO mice may be a reflection of morphologic changes in brain regions, such as the hippocampus, an area known to be involved in anxiety ([@bib4]), and the cerebellum, the control center for motor function and coordination ([@bib32]). Indeed, we found that brains from *Susd4* KO mice were characterized by abnormal "hairy" basket cells surrounding Purkinje cell soma in the cerebellum, as well as decreased dendritic spine density on the pyramidal cells in the CA region of hippocampus.

The phenomenon of "hairy" basket cells in the cerebellum has been specifically described in degenerative human brains of individuals with cerebellar essential tremor that are characterized by progressive loss of Purkinje cells and degenerative axonal abnormalities ([@bib2], [@bib3], [@bib27]). Basket cells are GABAergic inhibitory interneurons distributed across different regions of the brain, including the cortex, hippocampus, and cerebellum. Basket cells send inhibitory synapses to the soma of target cells to control their overall potentials. Purkinje cells are the sole output of motor coordination from the cerebellar cortex ([@bib13]). Although the mechanism of increased "hairiness" of basket cells is not clear, one possibility is that it represents an accumulation of converging and reorganizing of basket-cell processes recruited from damaged Purkinje cells ([@bib13]). Similar hairy basket formation was detected in epileptic hippocampus specimens owing to loss of affected pyramidal cells innervated by the basket cells ([@bib1], [@bib7]). However, in the *Susd4* KO model, no apparent loss of Purkinje cells in the cerebellum occurred, indicating that SUSD4 may influence innervative synaptic formation between Purkinje and basket cells through a different mechanism.

Dendritic spines are membranous protrusions that neurons use to form the postsynaptic component of the excitatory synapse ([@bib37], [@bib45], [@bib61]). Given that spines are the site for neurons to receive synaptic transmission, changes in spine morphology and numbers can be a fundamental indicator of physiological or pathological changes in the brain ([@bib5], [@bib18], [@bib35], [@bib41]). The molecular mechanisms that regulate spine genesis (synaptogenesis) and removal (synaptic pruning) have been intensively studied ([@bib25], [@bib29], [@bib56]). Accumulating evidence has revealed that components of the complement system (C1q, C3, and C4) and microglia play important roles in regulation of synaptic refinement and elimination during developmental synaptogenesis in the CNS ([@bib33], [@bib44], [@bib47], [@bib59]). Activation of complement under pathological conditions can lead to excessive synaptic pruning by microglia and neuron degeneration, as has been reported for Alzheimer\'s disease and other cognitive or behavioral disorders ([@bib12], [@bib28], [@bib39]). In *Susd4* KO mouse brain, we found decreased dendritic spine density in hippocampal pyramidal neurons. SUSD4 has been shown to bind to C1q, a subunit of the first component (C1 complex) for the classic complement pathway, and inhibit formation of downstream C3 convertase ([@bib20]). The increased C1q protein expression and neuronal synaptic deposition, hypertrophic microglia, and reduced synaptic density of neurons in *Susd4* KO mice suggest that *Susd4* may regulate complement-dependent synaptic pruning by microglia.

The exact mechanism leading to the increase of C1q in the *Susd4* KO brain has not been established. The *Susd4* deletion does not affect C1qa mRNA levels indicating that the mechanism is likely post-transcriptional. One possibility is that SUSD4 can alter the C1q levels directly by accelerating C1q degradation, as described for other complement control protein-containing regulators, such as DAF/CR1 on the C3/C5 convertase and CSMD1/factor I on C4b/C3b ([@bib14], [@bib38], [@bib48]).

The human *SUSD4* locus resides on chromosome 1q41 and is frequently deleted in patients with 1q41q42 microdeletion syndrome ([@bib49]). Clinical features, which occur along a variable phenotypic spectrum, generally include severe developmental delay, seizures, as well as multiple congenital abnormalities. *DISP1* ([@bib23], [@bib24]), *TP53PB3* ([@bib66]), *WDR26* ([@bib51], [@bib64]), and *FOXO28* ([@bib8], [@bib64]) have each been implicated as genes responsible for some features of the deletion syndrome. Although *SUSD4* was included in the original description of the smallest region of deletion overlap among patients with 1q41q42 microdeletion syndrome ([@bib49]), further refinement has indicated that *SUSD4* is unlikely to be responsible for major features of the disease ([@bib23]). However, the demonstration here that *Susd4* has important functions in the mammalian CNS raises the possibility that it may be a contributory factor in neurologic symptom severity when it is deleted in conjunction with the major causative genes in the patients with 1q41q42 microdeletion syndrome.

In summary, we have demonstrated substantial neurologic abnormalities in mice in which the *Susd4* gene has been deleted. These findings suggest an important role for SUSD4 in the CNS and that it may act through regulation of C1q functions in the CNS. Finally, the linkage of *Susd4* expression to mammalian CNS function implicates the deletion of the *SUSD4* gene as a potential phenotypic modifier in 1q41q42 microdeletion syndrome.

Limitation of the Study {#sec3.1}
-----------------------

We have shown that deletion of SUSD4 increases the levels of C1q in the brain. Although previously shown as an *in vitro* complement system inhibitor, the mechanism by which SUSD4 regulates the complement system and C1q levels in brain is not known and is a subject for future research.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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========================

Document S1. Transparent Methods, Figures S1--S4, and Table S1
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